CHRONIC HEPATITIS C

This study tested whether adding prazosin, a drug usually used for high blood pressure, to standard hepatitis C treatment could reduce liver scarring. 112 adults with chronic hepatitis C (genotype 1 or 4) and severe liver fibrosis took part. Researchers measured changes in liver …

This study tested whether a new form of interferon (IFN alfa-2b XL) combined with ribavirin works better and causes fewer side effects than the standard treatment for chronic hepatitis C (genotypes 1 or 4). 84 adults who had not been treated before or had not responded to previou…

This study tested whether irbesartan, a blood pressure medication, can slow the progression of liver scarring (fibrosis) in adults with chronic hepatitis C who cannot take or did not respond to antiviral therapy. Over two years, 166 participants took either irbesartan or a placeb…

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 week…

This study looked at whether adding vitamin D to standard hepatitis C treatment could help patients with genotype 1 or 4 who had not responded to previous therapy. 32 adults with low vitamin D levels were enrolled. The goal was to see if vitamin D could make the antiviral drugs w…

This phase 2 study tested a combination of three drugs—telaprevir, peginterferon, and ribavirin—in 70 adults with both HIV and hepatitis C who had not been helped by standard treatment before. The goal was to see if this triple therapy could clear the hepatitis C virus from the b…

This phase 3 trial tested a drug called telaprevir (MP-424) combined with two standard hepatitis C drugs (peginterferon and ribavirin) in 10 people with genotype 2 hepatitis C who had not responded to previous treatment. The goal was to see if this combination could clear the vir…

This study tested a triple-drug combination—telaprevir, peginterferon, and ribavirin—in 109 adults with genotype 1 hepatitis C whose infection returned after previous treatment. The goal was to see if the new regimen could clear the virus from the blood 24 weeks after treatment e…

This study tested a new drug called MP-424 (telaprevir) added to standard therapy (peginterferon and ribavirin) for people with genotype 2 hepatitis C whose infection came back after previous treatment. The goal was to see if the combination could clear the virus for good. The tr…

This study tested whether higher doses of ursodeoxycholic acid (UDCA) could better lower liver enzymes in 596 adults with chronic hepatitis C. Participants received 150, 600, or 900 mg of UDCA daily for 24 weeks. The main goal was to see if the higher doses were more effective an…

This early-phase study tested MP-424 (telaprevir) in 10 patients with chronic hepatitis C genotype 1b. Participants took three 250 mg tablets every 8 hours for 12 weeks. The main goals were to check safety, how the drug moves through the body, and how it affects hepatitis C virus…

This study tested whether offering hepatitis C treatment at the same clinic where people receive opioid therapy leads to better outcomes than referring them to a separate infectious disease clinic. About 298 people on opioid therapy with chronic hepatitis C took part. The goal wa…

This study looked at two faster ways to test for hepatitis C in people who recently injected drugs and visit needle exchange programs. One method uses a fingerstick test with results in about an hour, and the other uses a dried blood spot sent to a lab. The goal was to see if the…

This study looked at how people with chronic liver disease (like hepatitis B, C, or fatty liver) respond to COVID-19 vaccines. About 233 adults had three visits over a year to check their immune response and see if they got COVID-19. The goal was to understand if liver disease af…